High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities

Norman,Ingrid; Hjerpe,Anders; Andersson,Sonia

doi:10.3892/or.2013.2538

High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities

Authors:
- Ingrid Norman
- Anders Hjerpe
- Sonia Andersson
View Affiliations

Affiliations: Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden, Department of Women's and Children's Health, Division of Obstetrics and Gynaecology, Karolinska Institutet, Elevhemmet H2:00, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden
Published online on: June 11, 2013 https://doi.org/10.3892/or.2013.2538
Pages: 695-700

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human papillomavirus (HPV) L1 capsid protein is only produced during a productive HPV infection at the end of the natural viral life cycle and is a major target of the immune response in women with HPV-related squamous intraepithelial lesions. We evaluated the usefulness of L1 detection by immunocytochemistry in high-risk (HR) HPV-positive women with minor cytological abnormalities detected at organised population-based cervical cancer screening in Sweden, and assessed the relationship with histological diagnoses. Cytological slides were immunocytochemically stained using an HPV L1-specific monoclonal antibody for all known HPV types. HPV DNA analysis was performed using Linear Array test. Out of thirteen L1-positive women infected with HPV16, only two (15.0%) progressed to cervical intraepithelial neoplasia grade 2 or worse (CIN2+); compared to four L1-positive women infected with other HR-HPV types. Among L1-positive women with CIN2+, 35.7% harboured both HR and low-risk HPV types, 25.0% harboured HR-HPV types only and 13.3% were infected with HPV16. Loss of L1 expression could be a prognostic marker for the development of preinvasive cervical lesions. We show that different HPV types may initiate a parallel oncogenic process, but only loss of L1 expression predicts the development of CIN2+, suggesting that HPV typing in combination with L1 detection could be used for more focused investigations of women with minor cytological abnormalities.

View Figures

View References

1	Bergstrom R, Sparen P and Adami HO: Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 81:159–166. 1999. View Article : Google Scholar : PubMed/NCBI
2	Gunnell AS, Ylitalo N, Sandin S, Spärén P, Adami HO and Ripatti S: A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev. 16:2641–2648. 2007. View Article : Google Scholar
3	Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P and Meijer CJ: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 354:20–25. 1999. View Article : Google Scholar : PubMed/NCBI
4	Muñoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 19:1–5. 2000.
5	Clifford GM, Smith JS, Aguado T and Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 89:101–105. 2003. View Article : Google Scholar : PubMed/NCBI
6	Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
7	Bosch FX and Muñoz N: The viral etiology of cervical cancer. Virus Res. 89:183–190. 2002. View Article : Google Scholar : PubMed/NCBI
8	zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002.PubMed/NCBI
9	Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:518–527. 2003.
10	Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E and Wadell G: Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 171:1026–1030. 1995. View Article : Google Scholar : PubMed/NCBI
11	Benton C, Shahidullah H and Hunter JAA: Human papillomavirus in the immunosuppressed. Papillomavirus Rep. 3:23–26. 1992.
12	Stanley M: Immune responses to human papillomavirus. Vaccine. 24(Suppl 1): S16–S22. 2006. View Article : Google Scholar
13	Song SH, Lee JK, Lee NW, Saw HS, Kang JS and Lee KW: Interferon-γ (IFN-γ): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol. 108:543–548. 2008.
14	Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D and Stanley MA: Immunological events in regressing genital warts. Am J Clin Pathol. 102:768–774. 1994.PubMed/NCBI
15	Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R and Abadi M: Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 11:483–488. 2002.
16	Griesser H, Sander H, Hilfrich R, Moser B and Schenck U: Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol. 26:241–245. 2004.PubMed/NCBI
17	Hilfrich R and Hariri J: Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol. 30:78–82. 2008.
18	Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr and Young N; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 287:2114–2119. 2002. View Article : Google Scholar : PubMed/NCBI
19	Richart RM: Cervical intraepithelial neoplasia. Pathol Annu. 8:301–328. 1973.PubMed/NCBI
20	Brismar S, Johansson B, Borjesson M, Arbyn M and Andersson S: Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol. 201:17.e1–17e8. 2009. View Article : Google Scholar : PubMed/NCBI
21	Melsheimer P, Kaul S, Dobeck S and Bastert G: Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol. 47:124–128. 2003. View Article : Google Scholar : PubMed/NCBI
22	Griesser H, Sander H, Walczak C and Hilfrich RA: HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early squamous dysplastic lesions. Am J Clin Pathol. 132:840–845. 2009.PubMed/NCBI
23	Luostarinen T, af Geijersstam V, Bjorge T, Eklund C, Hakama M, Hakulinen T, Jellum E, Koskela P, Paavonen J, Pukkala E, Schiller JT, Thoresen S, Youngman LD, Dillner J and Lehtinen M: No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer. 80:818–822. 1999. View Article : Google Scholar : PubMed/NCBI
24	Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P and Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 119:1095–1101. 2006. View Article : Google Scholar : PubMed/NCBI